MedTrace Logo

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

NCT04640870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2020-12-23

No results posted yet for this study

Summary

This is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC) who had been treated with Afatinib at any line.

Conditions

  • Non Small Cell Lung Cancer
  • EGF-R Positive Non-Small Cell Lung Cancer
  • EGFR Gene Mutation

Interventions

DRUG

Afatinib

Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Ioannis Mountzios, MD · Henry Dunant Hospital Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-15
Primary Completion
2020-03-31
Completion
2020-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640870 on ClinicalTrials.gov